Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to ...

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with ...

A registry-based digital strategy that identified untreated patients and invited them to a telephone consultation more than ...

Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to ...

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary ...

Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional ...

The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in ...

Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) ...

Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear.

Brain diseases, including dementia, have long been studied using experimental animals such as mice. However, differences ...

Researchers have uncovered early molecular warning signs of inflammatory bowel disease, revealing the condition can begin ...